NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte

CompletedN/A

Sponsor: Inmunotek S.L.

Conditions: Mite Allergy, Dermatophagoides Farinae Allergy, Dermatophagoides Pteronyssinus Allergy, Rhinitis, Allergic, Asthma

Interventions: Clustoid® Max Forte

Countries: Spain

House dust mites are the main source of allergies in indoor environments. They are predominant in coastal areas, with the Canary Islands being the autonomous community with the highest percentage of patients with rhinoconjunctivitis due to sensitisation to these mites (94.7%). Immunotherapy is indicated for the treatment of allergic rhinoconjunctivitis and is capable of altering the natural course of allergic diseases. The aim of the study was to evaluate the efficacy and safety of Clustoid® Max Forte in the treatment of patients with respiratory allergy to Dermatophagoides/Blomia tropicalis.

Eligibility overview

Sex: ALL

Age: 5 Years to 65 Years

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. The study population consists of patients with respiratory allergic disease who are indicated for treatment with Clustoid® Max Forte immunotherapy according to standard clinical practice.
2. Age between 5 and 65 years, with no gender differences.
3. Who have received immunotherapy for at least one year.

Exclusion Criteria:

1.Patients who have received immunotherapy with airborne allergens prior to the treatment to be evaluated in this study.

Locations (2)

Santa Cruz de Tenerife, Canary Islands, Spain
Santa Cruz de Tenerife, Canary Islands, Spain